NHSA and NHC launch special medical insurance funds malpractice rectification



The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) released a notification in relation to rectifying the utilization of special medical insurance funds. The aim is to standardize diagnosis and treatment services and charging behaviors in the designated medical institutions, ratchet up refined management of medical institutions, and secure safe, efficient, and rational use of medical insurance funds.

All designated medical institutions in China are involved, as are the medical services and expenses covered by the basic medical insurance funds payment scope since January 1, 2018. They will be rectified on a case-by-case basis, with an emphasis on unreasonable charges, items (drugs) swapping, unstandardized diagnosis and treatment, and fictional services.

Reference:

Related news
The National Health Commission led seven other ministries in releasing an opinions document focused on “Further Regulating Medical Behaviors and Promoting Reasonable Medical Inspections".
The Center for Drug Evaluation (CDE) released the 38th batch of chemical generic reference preparations used as benchmarks for generic quality consistency evaluation (GQCE) work.
The National Health Commission’s (NHC) science, technology and education department draft “Measures on the Management of Investigator Initiated Clinical Studies”.
The National Health Commission (NHC) and other relevant bodies released a list of drugs in national supply shortage, and drugs that are clinically essential but deemed "at risk" of shortage.
The National Health Commission (NHC), Ministry of Science and Technology (MOST), National Healthcare Security Administration (NHSA), China National Intellectual Property Administration (CNIPA), and the National Medical Products Administration (NMPA) together released a second list of drugs recommended for generic development.
Recent news
Russian firm Binnopharm Group and India's Glenmark Pharmaceuticals will collaborate on the localized production of the antiviral drug favipiravir in Russia.
A Phase III clinical trial (CT) evaluating Janssen’s HIV vaccine candidate was recently picked up in Argentina after the National Administration of Drugs, Food and Medical Technology (ANMAT) last year temporarily suspended all preventive studies that were not related to COVID-19.
Suzhou-based circulating tumor cells (CTC) specialist Junhui Biotech Co., Ltd struck a strategic partnership with compatriot firm BGI Group (XSHE:300676) subsidiary MGI Tech.
Beijing-based EdiGene Inc., announced an approval nod from the Center for Drug Evaluation (CDE) to initiate a clinical study for ET-01, a CRISPR/Cas 9 gene-editing therapeutic candidate for patients with transfusion dependent β-thalassemia.
Brazil’s Congress last week announced a bill that proposes tax exemptions for drug makers that donate their products to organizations deemed of public interest by the National Health Surveillance Agency (ANVISA).
India’s Bharat Biotech and Brazilian pharmaceutical Precisa Medicamentos last week signed an agreement to supply the former’s SARS-CoV-2 vaccine Covaxin in Brazil, prioritizing the public sector.
BeiGene has a new partner for global development of its programmed death-1 (PD-1) candidate tislelizumab after signing a co-development and commercialization deal with Swiss major Novartis focused on the territories of North America, Japan, EU and six other European countries.
  • 1611036123603
  • China
Analytics Snapshot


Analytics Snapshot